Effects of Proteasome Inhibitor MG132 on Cell Proliferation, Apoptosis, and Cell Cycle in HEC-1B and Ishikawa Cells

ZHANG Qin, HUANG Juan, LI Dan-qing

Abstract

To study the anti-cancer activities of Z-Leu-Leu-Leu-cho (MG132) against human endometrial carcinoma HEC-1B and Ishikawa cells and the potential of MG132 in human endometrial cancer therapy. Methods HEC-1B and Ishikawa cells were treated with MG132. Cell proliferation was assessed by MTT while cell apoptosis rate and cell-cycle distribution were assessed by flow cytometry. Results The proliferation of HEC-1B and Ishikawa cells was inhibited by MG132 and cell proliferation was significantly inhibited with the raised concentration of MG132 (P<0.01), Ishikawa cells were more sensitive than HEC-1B cells to MG132. MG132 could induce the apoptosis of HEC-1B and Ishikawa cells (P=0.000). Cell cycle analysis indicated that the percentage of HEC-1B cells was increased in G2 phase (P<0.05) while Ishikawa cells’ was increased in G1 and G2 phase (P<0.05). Conclusion Proteasome inhibitor MGl32 could inhibit the proliferation, promote cell apoptosis, and block the cell cycle of HEC-1B and Ishikawa cells. MG132 may be a potential treatment for endometrial cancer.

Keywords: MG132, Endometrial cancer, Proliferation, Apoptosis, Cell cycle 


Full Text:

PDF


References


LeckerSH, Goldberg AL. Mitch WE. Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. J Am Soc Nephrol.2006; 17(7): 1807-1819.

Shirley RB. Djebbar IK, Patel DM, el al. Combination of proteasomal inhibitors lactacystin and MG 132 induced synergistic apoptosis in prostate cancer cells. Neoplasia,2005; 7 (12);1104-1111.

Mani A, Gelmann EP. The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol,2005;23(21) ;4776-4789.

Han YH, Park WH. MG132 as a proteasome inhibitor induces cell growth inhibition and cell death in A549 lung cancer cells via influencing reactive oxygen species and GSH level. Hum Exp Toxicol, 2010;29(7)j607-614.

Stoll SJ, Pitt SC, Chen H. Follicular thyroid cancer cell growth inhibition by proteosome inhibitor MG132. J Surg Res, 2009;156(1):39-44.

Saulle E, Petronelli A, Pasquini L. el al. Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis. Apoptosis,2007; 12(4):635-655.

Sterz J, von Metzler I, Hahne J, el al. The potential of proteasome inhibitors in cancer therapy. Expert Opin Inv Drug,2008;17(6) :879-895.

Han YH, Moon HJ, You BR, el al. The attenuation of MG132, a proteasome inhibitor, induced A549 lung cancer cell death by p38 inhibitor in ROS-independent manner. Oncol Res, 2010;18(7);315-322.

Dolcet X, Llobet D, Encinas M, el al. Proteasome inhibitors induce death but activate NF-jcB on endometrial carcinoma cell lines and primary culture explants. J Biol Chem, 2006; 281 (31):22118-22130.

Zanotto-Filh A, Delgado-Canedo А, Schroder R. al. The pharmacological NF-,cB inhibitors BAY117082 and MG132 induce cell arrest and apoptosis in leukemia cells through ROS- mitochondria pathway activation. Cancer Lett, 2010; 288 ( 2): 192-203.

Zhang Y, Shi Y, Li X, et al. Proteasome inhibitor MG132 reverses multidrug resistance of gastric cancer through enhancing apoptosis and inhibiting P-gp. Cancer Biol Ther. 2008;7(4);540-546.

Pajonk F. van Ophoven A. Weissenberger C. et al. Proteasome inhibitor MG132 sensitizes PC-3 prostate cancer cells to ionizing radiation by a DNA-PK-independent mechanism. BMC Cancer,2005;5(76); 1-12.


Refbacks

  • There are currently no refbacks.